Teresa, There are several points in this debate that I think are worth chatting about. In addition to the fundamental debate over the safety of vaccines as a whole, this case highlights the juncture between politics, community health, and big pharm/money-making ventures. Billions of dollars have been spent by Merck trying to push through legislation to mandate a vaccine that has been approved by the FDA for less than 5 years - you bet I think they are trying to push through this legislation before the other company gets there version of the vaccine out on the market and takes profits away from Merck. It would be so unfortunate for the fellows over at Big Pharm if the same amount of resources and energy were poured into an educational campaign regarding nutritional therapy for cervical dysplasia. Anyways, I attached some links below to articles that I found interesting. I will print out pertinent ones for class.
**There is much debate around the efficacy of the vaccine in the long-term. While articles like this one are out there, we have to pay attention to the short-term nature of our knowledge around the efficacy particularly when one notes that the average age women are diagnosed with HPV is not until after the approved time frame for administration of the vaccine.
Long-term efficacy of human papillomavirus vaccination
Kevin A. AultCorresponding Author Contact Information, a, E-mail The Corresponding Author aDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Drive, Atlanta, GA 30064, USA Received 24 July 2007. Available online 12 October 2007.
**Info on 2007 State Legislation concerning mandating the HPV vaccine: http://www.ncsl.org/programs/health/HPVvaccine.htm
**More insight into the information that is being dispelled out there. This is what the CDC has to say to healthcare providers:
More info for Clinical Correlates
There are several points in this debate that I think are worth chatting about. In addition to the fundamental debate over the safety of vaccines as a whole, this case highlights the juncture between politics, community health, and big pharm/money-making ventures. Billions of dollars have been spent by Merck trying to push through legislation to mandate a vaccine that has been approved by the FDA for less than 5 years - you bet I think they are trying to push through this legislation before the other company gets there version of the vaccine out on the market and takes profits away from Merck. It would be so unfortunate for the fellows over at Big Pharm if the same amount of resources and energy were poured into an educational campaign regarding nutritional therapy for cervical dysplasia. Anyways, I attached some links below to articles that I found interesting. I will print out pertinent ones for class.
**There is much debate around the efficacy of the vaccine in the long-term. While articles like this one are out there, we have to pay attention to the short-term nature of our knowledge around the efficacy particularly when one notes that the average age women are diagnosed with HPV is not until after the approved time frame for administration of the vaccine.
Long-term efficacy of human papillomavirus vaccination
Kevin A. AultCorresponding Author Contact Information, a, E-mail The Corresponding Author
aDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Drive, Atlanta, GA 30064, USA
Received 24 July 2007. Available online 12 October 2007.
**Info on 2007 State Legislation concerning mandating the HPV vaccine:
http://www.ncsl.org/programs/health/HPVvaccine.htm
**More insight into the information that is being dispelled out there. This is what the CDC has to say to healthcare providers:
http://www.cdc.gov/std/hpv/hpv-vacc-hcp-3-pages.pdf
-sara